Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna, Inc. (NASDAQ:MRNA) shares are picking up momentum after a steep sell-off on Monday, triggered by a scientific publication that suggested booster doses are unwarranted at this point of time. The company released a statement Wednesday that said incremental data from the Phase 3 COVE study suggested waning immunity a year after the first two doses — a supporting argument in favor of a booster dose.

Moderna Analysts Debate Need For Biopharma's COVID-19 Booster Shot

Today, Benzinga's options scanner spotted 12 uncommon options trades for Moderna (NASDAQ:MRNA). The overall sentiment shows 41.67% of the big-money traders are bullish on the stock and 58.33%, bearish.

Follow What Smart Money Traders Are Doing With Moderna

The fast-spreading delta variant is a whole new ball game for Covid-19 vaccines and ending the pandemic, Moderna President Stephen Hoge said.

Delta variant is so contagious it 'raises the bar' for Covid vaccines, Moderna president says

Moderna, Inc. (NASDAQ: MRNA) received the first full approval for its COVID-19 vaccine, about eight months after the shot was first accorded emergency use authorization. What Happened: Massachusetts-based Moderna said Health Canada, the nation's drug regulator, approved the new drug submission for its COVID-19 vaccine for active immunization to prevent COVID-19 in individuals 12 years of age and older.

Moderna Gets Full Approval Of COVID-19 Vaccine In Canada (Ahead Of US)

BioNTech SE

Pfizer

Amid rising coronavirus cases, PFE and MRNA are trying to make booster doses of their COVID-19 vaccine available for US citizens. An FDA meeting is scheduled tomorrow to discuss Comirnaty's booster dose.

Pfizer, Moderna Support COVID Vaccine Booster Before FDA Meet

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces Health Canada approves its COVID-19 vaccine.

Moderna Announces Health Canada Approves its COVID-19 Vaccine

Moderna said data suggested immunity from its vaccine fell over time - but the shot still appeared to stop severe COVID-19 for a long time.

Moderna says a study showed falling COVID-19 immunity over time and a need for boosters - even though most 'breakthrough' infections weren't severe

Moderna Inc (NASDAQ: MRNA) shared a new follow-up analysis through 1 year in the Phase 3 COVE study, suggesting a lower risk of breakthrough infection in participants vaccinated more recently (median 8 months after the first dose) than participants vaccinated last year (median 13 months after the first dose).  Related Link:   Pfizer Builds Case For COVID-19 Booster As Protection Wanes Over Time

After Pfizer, Now Moderna Touts Data Supporting COVID-19 Booster Dose

AMC Entertainment

Lordstown Motors

Certain analysts and investment banks see these stocks losing a majority of their value.

3 Ultra-Popular Stocks With 81% to 98% Downside, According to Wall Street

Pharmaceutical group Moderna MRNA, +1.58% said a study of breakthrough COVID-19 cases among vaccinated individuals supports the need for a booster shot. In a news release on Wednesday, Moderna identified 88 breakthrough COVID cases among 11,431 people vaccinated between December 2020 and March 2021, but 162 cases in the group who got their shots between July and October of last year.

Moderna study shows waning immunity for COVID shots, supports booster

The company said it believes booster shots are necessary “to maintain high levels of protection” as it saw 36% more “breakthrough infections” in people who got the vaccine last year.

Moderna Vaccine Highly Effective Against Delta—But Protection Against Infection Wanes Over Time, New Data Suggests

The U.S. drugmaker shared a new analysis that showed the incidence of breakthrough Covid cases was less frequent in people who were more recently vaccinated.

Moderna releases new data on Covid breakthrough cases it says supports need for booster shots

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna highlights new clinical data on its COVID-19 vaccine.

Moderna Highlights New Clinical Data on its COVID-19 Vaccine

Etsy

Lululemon Athletica

Etsy, Inc (NASDAQ:ETSY), Lululemon Athletica (NASDAQ:LULU) and Moderna, Inc (NASDAQ:MRNA) have all settled into bullish flag patterns on the daily chart. The bull flag pattern is created with a sharp rise higher forming the pole, which is then followed by a consolidation pattern that brings the stock lower between a channel with parallel lines.

Etsy, Lululemon, Moderna Form Bullish Patterns: What To Watch

AbCellera Biologics

AbCellera Biologics Inc (NASDAQ: ABCL) has entered into a research collaboration and license agreement with Moderna Inc (NASDAQ: MRNA) for antibodies for mRNA medicines. The collaboration will leverage AbCellera's AI-powered technology to search and analyze natural immune responses to identify therapeutic antibodies against up to six targets selected by Moderna.

AbCellera Shares Are Moving Higher On Licensing Pact With Moderna

Efforts by the World Health Organization to establish a hub for COVID-19 vaccine production in Africa will focus on recreating the technology used by Moderna Inc (NASDAQ: MRNA) in its messenger-RNA-based vaccine. However, due to the lack of talks with the Company, the project may take time to get off, Reuters reports citing a senior WHO official.

WHO-Backed Africa Vaccine Hub To Recreate Moderna COVID-19 Shot: Reuters

Affirm

Veteran trader David Green was back live trading on Benzinga Tuesday morning, and the long-time trader made some trades in some big-name stocks such as Affirm Holdings Inc (NASDAQ: AFRM), AMC Entertainment Holdings (NYSE: AMC) and Moderna Inc (NASDAQ: MRNA). AMC's stock had a strong day on Monday, following Walt Disney Co's (NYSE: DIS) announcement that the rest of Disney's 2021 movies will exclusively have in-theater premiers.

Why This Former NYSE Trader Bought Shares of AMC, Affirm And Moderna On Tuesday

Apple

Albemarle

Baker Hughes Co

Duke Realty

GameStop

Netflix

Momentum stocks rely on a strategy of buying into strength. These performers are all worth buying into at the moment.

7 Momentum Stocks That Show No Signs of Slowing Down

Investors appear to be buying on the dip after yesterday's sell-off.

Why Moderna Stock Is Bouncing Back Today

The success of the company's Covid-19 vaccine helps to validate the safety and efficacy of Moderna's mRNA technology, to an extent, and likely reduces the risk surrounding the rest of Moderna's sizable pipeline which has developments ranging from vaccines for infectious diseases to drugs targetin.

Moderna's R&D Day Indicates Covid-19 Will Remain The Biggest Driver Of The Stock

Novavax

Vaxart

Here's Some Good News for Vaccine Stock Investors

Why Moderna, Pfizer, and Other Vaccine Stocks Dropped Today

Adobe

U.S. indices were trading lower again Monday on continued weakness as investors continue to weigh coronavirus delta variant concerns, inflation worries and Fed tapering signs. The SPDR S&P 500 ETF Trust (NASDAQ: SPY) gained 0.26% to $446.58

Moderna, Adobe Lead The Nasdaq-100 Lower

Johnson & Johnson

The FDA is trying to make available a safe and effective COVID-19 vaccine for use in children below 12 years of age as soon as possible.

Will COVID-19 Vaccines for Children be Available by Year-End?

Coronavirus vaccine stocks Pfizer Inc. (NYSE: PFE), Moderna, Inc. (NASDAQ: MRNA), BioNTech SE (NASDAQ: BNTX) and Novavax, Inc. (NASDAQ: NVAX) were trading notably lower Monday. What Happened: A new review authored by a group of international scientists and published by the Lancet suggeststhat booster doses of the COVID-19 vaccine may not be currently needed for the general population.

News for Moderna Stock (MRNA)